LOREM IPSUM DOLOR

LOREM IPSUM DOLOR LOREM

Abstract : well-stuctured
Abstract
Background
Atopic dermatitis (AD) is a chronic, relapsing, pruritic, inflammatory skin disease. The
estimated prevalence of AD is 25% among children and up to 2 to 3% for adults. Although
most adults with AD have mild disease, up to 30% have moderate to severe disease as
assessed by dermatologists using clinical disease severity scales. It is estimated that
approximately 10% of adult patients have recalcitrant AD that does not respond adequately
to topical anti-inflammatory treatment and requires phototherapy and/or systemic therapy
with immunosuppressants

This is a follow-up to a previous publication that considered systemic

treatment options for adults with AD. The goal is to provide a patient-
focused approach to the identification and management of adults with AD
who require systemic treatment.
Methods

A working group of clinicians experienced in managing AD was convened to

review and discuss current evidence on the identification and clinical
management of adults with moderate to severe AD.

The review also provided a simple framework for evaluating systemic

treatments for AD.
A literature search was conducted for articles on guidelines for the
management of AD, clinical outcome measures in AD, and clinical trials of
systemic treatments for adult AD, including patient demographics and selection
criteria.
Current Treatments for AD
Emollient or moisturiser therapy and topical anti-inflammatory therapy
in the form of calcineurin inhibitors or corticosteroids are
recommended as the first-line treatment for AD.
1

Systematic reviews of immunosuppressant therapies for AD suggest

2 generally poor-quality evidence to support their efficacy and safety.

3
In 1 single-centre study, a third of patients who had been treated with
systemic therapy had received more than 1 immunosuppressive agent,
with the majority of discontinuations due to lack of efficacy and/or
intolerability
THANK
YOU